Revenio Group (REG1V) Q1 2025 earnings summary

Executive summary

• Net sales reached EUR 26.1 million in Q1 2025, up 10.5% year-over-year, with currency-adjusted growth at 12%.

• EBIT rose 28.6% to EUR 6.6 million, representing 25.4% of revenue, marking a record quarter for profitability and top-line growth.

• Growth was organic across all regions and product lines, with notable strength in the U.S., APAC (especially China and India), Europe, and Canada.

• Product launches and regulatory approvals, including FDA and CE for microperimeter, supported positive momentum.

• Healthy sales pipeline in the US, supported by a competitive product and solution offering.

Financial highlights

• Net sales: EUR 26.1 million (+10.5% year-over-year); currency-adjusted sales up 12%.

• EBIT: EUR 6.6 million (+28.6% year-over-year), representing 25.4% of net sales.

• EBITDA: EUR 7.7 million (+24.3% year-over-year); EBITDA margin 29.6%.

• EPS: EUR 0.157 (up from 0.137); cash flow from operations: EUR 4.7 million.

• Gross margin improved to 72.6% from 70.3% year-over-year, partly due to IFRS accounting changes.

Outlook and guidance

• Exchange rate-adjusted net sales for 2025 are expected to grow 6–15% from the previous year.

• Profitability, excluding non-recurring items, is expected to remain at a good level.

• Market uncertainty and tariffs contribute to a wider guidance range.